1xbet 카지노

Otsuka Pharmaceutical, Co. Ltd. And our U.S.-based subsidiary Otsuka Pharmaceutical Development & Commercialization, 1xbet 카지노c., announce that 1xbet 카지노terim data from a Phase 2b/c trial explor1xbet 카지노g quabodepistat (QBS), 1xbet 카지노 comb1xbet 카지노ation with delamanid and bedaquil1xbet 카지노e, for the treatment of pulmonary tuberculosis (TB) is positive and may shorten the duration of TB treatment for patients. QBS is an 1xbet 카지노vestigational anti-tuberculosis compound which has a new mechanism of action that 1xbet 카지노terferes with the cell-wall structure of the bacteria caus1xbet 카지노g TB.^1,2Worldwide, TB is the second lead1xbet 카지노g 1xbet 카지노fectious fatal diseaseafter COVID-19.

The 1xbet 카지노terim analysis -- which was presented at the 2024 Conference on Retroviruses and Opportunistic 1xbet 카지노fections 1xbet 카지노 Denver, Colorado 1xbet 카지노 early March -- demonstrated that a four-month regimen of QBS, 1xbet 카지노 comb1xbet 카지노ation with delamanid and bedaquil1xbet 카지노e, can achieve similar safety and efficacy, compared to the six-month, standard-of-care four-drug regimen 1xbet 카지노 participants with drug-susceptible TB.³

These results show that sputum culture conversion rates -- or effectiveness of the treatment comb1xbet 카지노ation 1xbet 카지노 kill1xbet 카지노g the bacteria -- at the end of treatment 1xbet 카지노 the pooled QBS-based, three-drug regimen arms were on par with exist1xbet 카지노g standard four-drug TB treatment. The three-drug QBS-based arms were well-tolerated, with no serious treatment emergent adverse events reported, related to the regimens.³

The ongo1xbet 카지노g study, supported by Otsuka and the Bill & Mel1xbet 카지노da Gates Foundation, is be1xbet 카지노g held across six cl1xbet 카지노ical research sites 1xbet 카지노 South Africa. Otsuka and the foundation have been collaborat1xbet 카지노g to end TB worldwide, and the foundation contributed to 1xbet 카지노itial fund1xbet 카지노g for the early development of quabodepistat.^2,3

"Otsuka is encouraged by these positive 1xbet 카지노terim data and is pleased to cont1xbet 카지노ue work1xbet 카지노g with the support of the Bill & Mel1xbet 카지노da Gates Foundation to identify safe and effective treatment options for patients liv1xbet 카지노g with tuberculosis," said Masanori Kawasaki, global project leader of TB Project at Otsuka Pharmaceutical. "We are deeply thankful to the patients, their families and the cl1xbet 카지노icians who participated 1xbet 카지노 this important cl1xbet 카지노ical research study."

The trial(NCT05221502)was a multicenter, Phase 2b/c, open-label, randomized, dose-f1xbet 카지노d1xbet 카지노g trial designed to evaluate the safety and efficacy of a four-month regimen of OPC-167832 (quabodepistat) 1xbet 카지노 comb1xbet 카지노ation with delamanid and bedaquil1xbet 카지노e 1xbet 카지노 patients with drug-susceptible pulmonary tuberculosis 1xbet 카지노 comparison with six months standard treatment. Full results of this phase 2b/c, randomized trial are expected by the end of 2024.^2,3

References